Relative contributions of basal vs postprandial hyperglycaemia to overall glycaemic control in newly diagnosed Chinese adults with type 2 diabetes before and after 3 months' intensive glucose‐lowering therapy

Understanding the relative contributions of basal and postprandial hyperglycaemia (BH and PPH) to hyperglycaemia is pivotal to optimising the therapeutic strategies for type 2 diabetes (T2D). We used continuous glucose monitoring (CGM) to quantify longitudinal changes in the relative contributions of BH and PPH to overall hyperglycaemia in 22 treatment‐naïve Han Chinese adults with T2D before and after 3 months of intensive glucose‐lowering therapy. At baseline (HbA1c 10.0 ± 0.3%), BH predominated, contributing 73–77% of overall hyperglycaemia. Following treatment (HbA1c 7.1 ± 0.2%), the contribution of BH decreased markedly (35–38%), while PPH became the dominant contributor of hyperglycaemia (~62–66%). The improvement in glycaemic control was also accompanied by enhanced insulin secretion and sensitivity, without changes in gastric emptying. These findings provide longitudinal, CGM‐based evidence of a dynamic shift in glycaemic determinants with therapy. Therapeutic strategies should be adapted accordingly, with initial focus on BH followed by increasing emphasis on PPH as glycaemic control improves.